| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446266 | HIKMA | Combination composition |
Oct, 2031
(7 years from now) | |
| US11896567 | HIKMA | Combination composition |
Oct, 2031
(7 years from now) | |
| US11389416 | HIKMA | Aqueous formulation comprising paracetamol and ibuprofen |
Jul, 2035
(11 years from now) | |
| US11213498 | HIKMA | Aqueous formulation comprising paracetamol and ibuprofen |
Jan, 2036
(11 years from now) | |
Combogesic Iv is owned by Hikma.
Combogesic Iv contains Acetaminophen; Ibuprofen Sodium.
Combogesic Iv has a total of 4 drug patents out of which 0 drug patents have expired.
Combogesic Iv was authorised for market use on 17 October, 2023.
Combogesic Iv is available in solution;intravenous dosage forms.
Combogesic Iv can be used as method of treating moderate to severe pain in adults as an adjunct to opioid analgesics.
The generics of Combogesic Iv are possible to be released after 14 January, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using ACETAMINOPHEN; IBUPROFEN SODIUM ingredient
Market Authorisation Date: 17 October, 2023
Treatment: Method of treating moderate to severe pain in adults as an adjunct to opioid analgesics
Dosage: SOLUTION;INTRAVENOUS
COMBOGESIC IV family patents
